Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Who shrank the drug factory? Briefcase-sized labs could transform medicine

Govind Rao demonstrating the, Biologically-derived Medicines on Demand (Bio-MOD system)

Credit: Rosem Morton for Nature

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature 575, 274-277 (2019)


Updates & Corrections

  • Correction 29 November 2019: An earlier version of this story erroneously stated that an MIT project to produce biologic drugs was led by Timothy Lu. In fact, the project was led by Christopher Love with input from Lu. The article neglected to mention that this team was able to create drugs comparable to FDA-approved drugs and cite the appropriate reference. Finally, the cost estimate for medicine-on-demand systems was ambiguous.


Latest on:

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links